Peptide News Digest

ADA 2026 Closes: Orforglipron ACHIEVE Beats Oral Semaglutide Head-to-Head, AstraZeneca Elecoglipron 10.5% Phase 2b + Lancet, Roche Enicepatide 22.5%, Boehringer Survodutide Fat-Loss Detail, Petrelintide Tolerability

ADA closes: orforglipron beats oral semaglutide head-to-head, elecoglipron 10.5%, Roche enicepatide 22.5%, survodutide fat-loss detail, plus new SoC.

10 stories · Covering clinical-trials, regulatory, industry

Editor's Note

Monday closed ADA 2026 with the meeting's densest set of obesity readouts. Lilly took its oral GLP-1 Foundayo to a Phase 3 win over oral semaglutide in ACHIEVE-3, with 37% of patients on the highest dose reaching an HbA1c below 5.7%, normal-range territory, against 12.5% on the comparator. AstraZeneca's elecoglipron joined the oral incretin field with 10.5% weight loss in VISTA, a Lancet publication, and a Phase 3 transition. Roche put hard numbers on the petrelintide and enicepatide combination strategy: 22.5% placebo-adjusted weight loss for enicepatide at 48 weeks and a tolerability case for the amylin analog petrelintide that targets the patients who quit GLP-1s for GI side effects. Boehringer added body-composition detail to survodutide's already-published topline (34% visceral and 63% liver fat reduction), and the ADA released revised Standards of Care that elevated cardiovascular and kidney risk to co-primary diabetes goals alongside HbA1c. The takeaway after four days: the oral, amylin, and combination threads now have real data behind them, and the field's center of gravity has moved beyond once-weekly injections of a single GLP-1.

Clinical Trials

Lilly Foundayo (Orforglipron) ACHIEVE Phase 3 Data at ADA: Head-to-Head Win Over Oral Semaglutide, FDA Filing in Q2

Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.

#eli-lilly #orforglipron #foundayo #achieve-3 #oral-glp-1 #type-2-diabetes #ada-2026
Clinical Trials

AstraZeneca Elecoglipron VISTA Phase 2b at ADA: 10.5% Weight Loss at 26 Weeks Versus 0.6% Placebo, Lancet Publication, Phase 3 Confirmed

AstraZeneca presented VISTA Phase 2b data at ADA 2026 with simultaneous Lancet publication. In adults with obesity or overweight plus comorbidity, oral elecoglipron 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, continuing to 11.8% by 36 weeks, alongside blood-pressure and inflammation reductions. The companion SOLSTICE T2D trial showed 1.9-point HbA1c reductions with 90% reaching HbA1c under 7% and 7.7% weight loss. AstraZeneca announced an extensive Phase 3 program covering obesity, T2D, and cardiovascular and kidney outcome trials.

#astrazeneca #elecoglipron #azd5004 #vista #solstice #oral-glp-1 #ada-2026 #lancet
Clinical Trials

Roche Enicepatide CT388-103 Phase 2 at ADA: 22.5% Placebo-Adjusted Weight Loss at 48 Weeks, 40% Reaching 25% Loss

Genentech presented Phase 2 CT388-103 data for enicepatide, the once-weekly GLP-1/GIP dual agonist, at the Roche investor event Monday June 8. The 48-week study produced 22.5% placebo-adjusted weight loss in adults with overweight or obesity, with 26% of participants losing more than 30% of body weight and almost 40% reaching at least 25%. Both enicepatide and petrelintide advance into Phase 3, and the planned Phase 2 multi-arm fixed-dose combination of the two starts mid-2026.

#roche #genentech #enicepatide #ct388-103 #glp-1-gip #phase-2 #ada-2026
Clinical Trials

Roche Petrelintide ZUPREME-1 at ADA: Amylin Analog Targets the 30-40% of Patients Who Quit GLP-1s for GI Tolerability

Roche presented ZUPREME-1 Phase 2 data for petrelintide, the once-weekly long-acting amylin analog licensed from Zealand Pharma, at the Monday June 8 investor event. The pitch hinges on tolerability: published topline showed up to 10.7% weight loss at 42 weeks versus 1.7% placebo, with discontinuation 4.8% vs 4.9% placebo and no vomiting at the maximally effective dose. Medical Daily framed the readout as a non-incretin option for the estimated 30-40% of patients who quit GLP-1s for GI side effects. Petrelintide advances to Phase 3 alongside enicepatide.

#roche #petrelintide #zealand-pharma #amylin #zupreme-1 #ada-2026 #tolerability
Clinical Trials

Boehringer Survodutide SYNCHRONIZE-1 Pre-Specified Body Composition: 34% Visceral Fat and 63% Liver Fat Reduction, Lean Mass Preserved

Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.

#boehringer-ingelheim #survodutide #synchronize-1 #synchronize-masld #body-composition #liver-fat #ada-2026
Regulatory

ADA Standards of Care in Diabetes 2026 Revised at Closing: Cardiovascular and Kidney Risk Reduction Elevated to Co-Primary Goal Alongside HbA1c

The ADA closed its 86th Scientific Sessions on June 8 with a formal revision to its Standards of Care that elevates cardiovascular and kidney risk reduction to a co-primary treatment goal alongside glycemic control, ending decades of practice in which HbA1c stood as the dominant benchmark. The shift formalizes a redefinition of diabetes care around the cardio-renal-metabolic axis that GLP-1, SGLT2, and finerenone evidence has driven, and pushes earlier GLP-1 and SGLT2 use from diabetes diagnosis.

#ada-2026 #standards-of-care #guidelines #cardiovascular #kidney-disease
Industry

ADA 2026 Oral GLP-1 Field Map After Monday: Foundayo, Aleniglipron, Elecoglipron, Ribupatide, HRS-7535

Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.

#oral-glp-1 #orforglipron #aleniglipron #elecoglipron #ribupatide #competitive-landscape
Industry

Roche Confirms Petrelintide-Enicepatide Phase 2 Combination Trial Starts Mid-2026

Genentech confirmed at its Monday investor event that the planned Phase 2 multi-arm fixed-dose combination of petrelintide (amylin analog) and enicepatide (GLP-1/GIP) starts mid-2026. The setup mirrors Novo's CagriSema and Lilly's Mounjaro-plus-amylin work, with Roche aiming for the same dual-mechanism economics that produced REIMAGINE 2's head-to-head win this week. Roche projected $9 billion in peak annual sales for the combined obesity pipeline at its Q1 print.

#roche #genentech #petrelintide #enicepatide #combination-therapy #amylin
Industry

Medscape Frames the Beyond-GLP-1 Pipeline at ADA 2026: Amylin, Triagonist, Antibody-Peptide, and Preclinical Acceleration

A Medscape ADA wrap on June 8 framed the post-GLP-1 era taking shape across the meeting: amylin analogs (petrelintide, cagrilintide, eloralintide) targeting GI-intolerance, triagonists (retatrutide), antibody-peptide conjugates (Amgen's maridebart cafraglutide/MariTide), and preclinical acceleration through AI peptide-design platforms. Each angle aims at the population gap that current GLP-1 monotherapy leaves: the patients who quit for tolerability, the ones who plateau, and the ones who need additional metabolic effects beyond appetite.

#ada-2026 #amylin #retatrutide #maridebart-cafraglutide #ai-drug-design #competitive-landscape
Industry

ADA 2026 Closes in New Orleans After Four Days: Retatrutide, CagriSema, Foundayo, Survodutide, Petrelintide, Elecoglipron, Mazdutide, and the New Standards of Care

The 86th ADA Scientific Sessions wrapped Monday June 8 after presenting Phase 3 retatrutide TRIUMPH-1/TRANSCEND-T2D-1, CagriSema REIMAGINE 1/2/3, Foundayo ACHIEVE 1-5, survodutide SYNCHRONIZE-1, petrelintide ZUPREME-1, enicepatide CT388-103, elecoglipron VISTA/SOLSTICE, mazdutide GLORY-2/DREAMS-3, zenagamtide Phase 2, plus the inaugural ADA Standards of Care in Overweight and Obesity. The next inflection points: the July 23-24 PCAC peptide-compounding meeting, August 28 ITM-11 PDUFA in NETs, and the Foundayo T2D filing in Q2.

#ada-2026 #wrap #new-orleans #pipeline #incretin #amylin